用于成人代谢功能障碍相关脂肪性肝病的胆汁酸
Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.
作者信息
Ashmawy Rehab E, Blyuss Oleg, Nikolova Dimitrinka, Pavlov Chavdar S, Gluud Christian, Andrenacci Paola J
机构信息
Faculty of Medicine, Helwan University, Cairo, Egypt.
Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
出版信息
Cochrane Database Syst Rev. 2025 Sep 2;9(9):CD014850. doi: 10.1002/14651858.CD014850.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of oral bile acid-based therapies versus no intervention or placebo, or versus a different bile acid-based therapy, at any dose or regimen, in adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估在任何剂量或治疗方案下，口服胆汁酸类疗法与不干预或安慰剂相比，或与不同的胆汁酸类疗法相比，对诊断为代谢功能障碍相关脂肪性肝病（MASLD）的成年人的益处和危害。
相似文献
1
Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.
Cochrane Database Syst Rev. 2025 Sep 2;9(9):CD014850. doi: 10.1002/14651858.CD014850.
2
Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis.
Cochrane Database Syst Rev. 2007 Jan 24(1):CD005160. doi: 10.1002/14651858.CD005160.pub2.
3
Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.
Cochrane Database Syst Rev. 2025 Jun 24;6(6):CD015524. doi: 10.1002/14651858.CD015524.pub2.
4
Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011648. doi: 10.1002/14651858.CD011648.pub2.
5
Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
Biomolecules. 2023 Sep 6;13(9):1356. doi: 10.3390/biom13091356.
6
Vitamin E for people with non-alcoholic fatty liver disease.
Cochrane Database Syst Rev. 2024 Oct 16;10(10):CD015033. doi: 10.1002/14651858.CD015033.pub2.
7
Ursodeoxycholic acid for primary biliary cirrhosis.
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD000551. doi: 10.1002/14651858.CD000551.pub3.
8
Bile acids for liver-transplanted patients.
Cochrane Database Syst Rev. 2010 Mar 17(3):CD005442. doi: 10.1002/14651858.CD005442.pub2.
9
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 30;3(3):CD011640. doi: 10.1002/14651858.CD011640.pub2.
10
Bile acids for viral hepatitis.
Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD003181. doi: 10.1002/14651858.CD003181.pub2.
本文引用的文献
1
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
2
Effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
BMJ Open. 2024 May 30;14(5):e078053. doi: 10.1136/bmjopen-2023-078053.
3
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9.
4
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
5
Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis.
Cell Metab. 2023 Oct 3;35(10):1752-1766.e8. doi: 10.1016/j.cmet.2023.07.011. Epub 2023 Aug 16.
6
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
7
Changing epidemiology, global trends and implications for outcomes of NAFLD.
J Hepatol. 2023 Sep;79(3):842-852. doi: 10.1016/j.jhep.2023.04.036. Epub 2023 May 9.
8
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
9
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
10
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
Cardiovasc Diabetol. 2022 Dec 3;21(1):270. doi: 10.1186/s12933-022-01697-0.
Zotero 插件